Corbus Pharmaceuticals (CRBP) has released an update to notify the public and investors about a regulation fd disclosure.
Corbus Pharmaceuticals Holdings, Inc. announced results from the Phase 1 clinical trial of SYS6002 (CRB-701) on January 26, 2024, with data presented at the 2024 ASCO GU Symposium. Along with the press release, the company updated its business presentation for management use. The materials provided to the SEC are for informational purposes and are not considered “filed” under any securities laws.
For further insights into CRBP stock, check out TipRanks’ Stock Analysis page.
